Search

• GSK receives positive top-line results from sirukumab phase III programme supporting regulatory filings for rheumatoid arthritis in 2016

  Media

  GSK today announced it has received positive top-line results from the phase III programme investigating sirukumab

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-top-line-results-from-sirukumab-phase-iii-programme-supporting-regulatory-filings-for-rheumatoid-arthritis-in-2016/

  First published: 16 December 2015

• GSK’s global HIV business ViiV Healthcare to acquire Bristol-Myers Squibb’s R&D HIV assets

  Media

  Two transactions further strengthen HIV pipeline and outlook

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-global-hiv-business-viiv-healthcare-to-acquire-bristol-myers-squibb-s-rd-hiv-assets/

  First published: 18 December 2015

• GSK adds detailed clinical trial data to multi-sponsor request system as part of continued commitment to data transparency

  Media

  GSK added its anonymised patient-level data from the online request system it launched in May 2013 to a new multi-sponsor request system.

  https://www.gsk.com/en-gb/media/press-releases/gsk-adds-detailed-clinical-trial-data-to-multi-sponsor-request-system-as-part-of-continued-commitment-to-data-transparency/

  First published: 02 January 2014

• GSK announces phase III study with darapladib did not meet primary endpoint in patients following an acute coronary syndrome

  Media

  GSK announced headline results from its second phase III study with darapladib evaluating efficacy in adults with acute coronary syndrome.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-iii-study-with-darapladib-did-not-meet-primary-endpoint-in-patients-following-an-acute-coronary-syndrome/

  First published: 13 May 2014

• GSK receives positive CHMP opinion for Incruse® (umeclidinium) for the treatment of COPD

  Media

  GSK announced that EMA's CHMP is recommending marketing authorisation for umeclidinium, treatment to relieve symptoms in patients with COPD.

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-for-incruse-umeclidinium-for-the-treatment-of-copd/

  First published: 20 February 2014

• Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer

  Media

  GSK announced its decision to stop the Phase III trial of MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer patients.

  https://www.gsk.com/en-gb/media/press-releases/update-on-phase-iii-clinical-trial-of-investigational-mage-a3-antigen-specific-cancer-immunotherapeutic-in-non-small-cell-lung-cancer/

  First published: 02 April 2014

• GlaxoSmithKline plc appoints Sir Philip Hampton to the Board of Directors

  Media

  GSK announced that Sir Philip Hampton will join the Board of the company as Non-Executive Director from 1 January 2015

  https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-appoints-sir-philip-hampton-to-the-board-of-directors/

  First published: 25 September 2014

• GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade™) (1)

  Media

  GSK announced submission to EMA for eltrombopag (Revolade™) for the treatment of patients with SAA who have insufficient response to IST.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-eu-regulatory-submission-seeking-additional-indication-for-eltrombopag-revolade-1/

  First published: 12 November 2014

• GSK launches first call for proposals for research in to non-communicable diseases in sub-Saharan Africa

  Media

  GSK launched first call for proposals for its Africa NCD Open Lab, to support much-needed scientific research into NCDs in Africa.

  https://www.gsk.com/en-gb/media/press-releases/gsk-launches-first-call-for-proposals-for-research-in-to-non-communicable-diseases-in-sub-saharan-africa/

  First published: 14 November 2014

• Regulatory update on transaction with Novartis

  Media

  GSK providing AN update relating to the major three-part transaction with Novartis AG (the Original Announcement).

  https://www.gsk.com/en-gb/media/press-releases/regulatory-update-on-transaction-with-novartis/

  First published: 26 November 2014